tokyo, October 8, 2024 /PRNewswire/ — Ciconia Bio Ventures Co., Ltd. (CEO, Founder CEO: Toshio Fujimoto“Ciconia” announced today that it has been established as a joint venture pursuant to a master agreement signed in November 2019. April 22, 2024 by Takeda Pharmaceutical Company (NYSE:) Limited (TSE: 4502/NYSE: TAK, President and CEO; Christoph Weber“Takeda”), Astellas Pharmaceutical Co., Ltd. (TSE: 4503, President and CEO: Naoki Okamura“Astellas”) and Mitsui Sumitomo (NYSE:) Bank (President and CEO: Akihiro Fukutome“SMBC”). (See the press release regarding the master agreement here.)
Ciconia aims to translate innovative technologies and drug discovery programs, seamlessly handling the entire process from initial drug discovery research to the establishment of biotechnology startups. japan Enter clinical application. The company leverages a wide range of promising drug discovery seeds from Japanese academia, biotech startups and pharmaceutical companies, focusing on establishing development strategies and acquiring new data to increase the value of these seeds and transform them into high-potential assets with greater potential. I will do it. Chances of success. The company will also bring together additional R&D funding and an experienced management team to launch new innovative startups, increasing the number of successful biotechnology ventures. japan. To achieve this goal of advancing innovative drug discovery programs primarily: japan Ciconia’s incubation activities, including entering the global pharmaceutical market, incubating globally competitive new drug discovery technologies, and fostering entrepreneurship, will be carried out in cooperation with academia, biotechnology ventures, and pharmaceutical companies around the world. japanIt is part of a joint effort to unlock the potential of the drug discovery ecosystem for the world.
A Siconia official said, “Siconia will evaluate seeds in the early stages of development and establish its own company based on the selected seeds to raise funds globally and promote global product development.” Toshio FujimotoCEO, Founding CEO of Ciconia. “Ultimately, we hope to deliver innovations that: japan to the world through our work.”
“The establishment of Ciconia is an important step forward for the company’s further growth. japanese “A new drug discovery ecosystem that will lead global R&D” Yasushi Kajiiresponsible person R&D Japan region From Takeda. “Leveraging our extensive experience supporting domestic and international ventures and entrepreneurs, we are committed to helping emerging startups in Ciconia scale globally with quality drug discovery seeds.”
“I look forward to the revitalization of Ciconia. japanese He continued, “We are working with various participants such as industry, government, and academia to build a new drug discovery ecosystem and provide innovative treatments to patients around the world through global expansion.” Tsukamoto IsseiPh.D., Head of Business Development, Astellas. He continued, “We will provide diversified support to Ciconia based on our new drug discovery, business expertise, and network we have built around the world.”
“We will support japanese We promote revival by promoting the development of new technologies and industries. Ciconia Bio Ventures Co., Ltd.An SMBC official added, “It is helpful in developing new drugs.”
for Ciconia Bio Ventures Co., Ltd.
location:
- Headquarters: 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-0012, japan
- tokyo Office: 3-11-5 Nihonbashihoncho, Chuo-ku tokyo 103-0023, japan
establishment: August 2024
Capital: approx. 600 million yen (including capital reserves)
Management Team:
- CEO, Founder CEO: Toshio Fujimoto
- COO/CBO: Tani Masaharu
- Interim CSO: Yoshinori Ikeura
Website: https://www.ciconiabioventures.com
